17
total announcements
SUDEEPPHRM.NS · 15 min delayed
Sudeep Pharma Limited
Sudeep Pharma Limited's Q1 FY27 earnings conference call highlights strong revenue growth of 27% YoY, driven by broad-based performance across pharma, food and nutrition, and specialty ingredient business, despite a challenging global operating environment.
Sudeep Pharma Limited
Sudeep Pharma Limited has corrected the number of attendees at its Annual General Meeting (AGM) from 45 to 44, with 5 from the promoter group and 39 from the public.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange about the link of recording of their earnings call held on 5th August 2026. The audio recording is available on their website and a transcript will be submitted separately.
Sudeep Pharma Limited
Sudeep Pharma Limited has submitted the Scrutinizer's report and voting results of the Annual General Meeting (AGM) held on August 4, 2026. The company has informed the Exchange regarding the resolutions passed at the AGM, including the re-appointment of a director, declaration of dividend, and ratification of remuneration to the Cost Auditors.
Sudeep Pharma Limited
Sudeep Pharma Limited has published unaudited financial results for the first quarter ended 30th June 2026 in newspapers, as per Regulation 30 and 47 of the SEBI (LODR) Regulations, 2015. The company has also informed about a borrower's default in repayment of loan and the classification of the loan as a Non-Performing Asset (NPA).
Sudeep Pharma Limited
Sudeep Pharma Limited has announced its Q1FY27 results, with revenue growing 27% year-on-year, driven by strong performance across its Pharma, Food & Nutrition, and Specialty Ingredients businesses. The company has also made progress on its strategic growth initiatives, including the Greenfield expansion and Sudeep Advanced Materials (SAM) project.
Sudeep Pharma Limited
Sudeep Pharma Limited has announced its Q1FY27 results, with revenue growing 27% year-on-year, driven by strong performance across its Pharma, Food & Nutrition, and Specialty Ingredients businesses. The company has also made progress on its strategic growth initiatives, including the Greenfield expansion and Sudeep Advanced Materials (SAM) project.
Sudeep Pharma Limited
Sudeep Pharma Limited has submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, to the National Stock Exchange and BSE, following a board meeting on August 4, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026, through video conferencing. The meeting was attended by directors, auditors, and shareholders. The company secretary introduced the directors and informed the members about the meeting's proceedings, including e-voting, statutory registers, and auditor reports. The meeting was conducted in accordance with the Ministry of Corporate Affairs and Securities and Exchange Board of India's circulars.
Sudeep Pharma Limited
Sudeep Pharma Limited has scheduled an earnings call with analysts and investors to discuss its operational and financial performance for the quarter ended June 30, 2026, on August 5, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has announced the record date for the payment of final dividend as July 23, 2026, subject to approval at the 37th Annual General Meeting on August 4, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange regarding the Integrated Annual Report for the Financial Year 2025-26 and the 37th Annual General Meeting (AGM) scheduled to be held on August 4, 2026. The company has sent a letter to shareholders providing the web-link to access the Integrated Report and the AGM Notice. The last date for submission of TDS exemption forms is July 22, 2026, and the record date for the final dividend is July 23, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming that all shares are held in electronic mode only.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange regarding the appointment of Mr. Milin Mehta as a Non-Executive Non-Independent Director on the Board of the Company, effective June 26, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange regarding the appointment of Mr. Milin Mehta as a Non-Executive Non-Independent Director on the Board of the Company, effective June 26, 2026.
Sudeep Pharma Limited
Sudeep Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the securities of the Company shall be closed for designated persons from Wednesday, 1st July 2026 and shall remain closed till 48 hours after the declaration of the un-audited financial results of the Company for quarter ending on 30th June 2026.